Your payment is in progress...
  +1 (704) 266-3234

Global Biologics And Biosimilars Market Growth 2020-2025

Published on: Oct 2020 | From USD $3660 | Published By: LP INFORMATION INC. | Number Of Pages: 165

According to this study, over the next five years the Biologics and Biosimilars market will register a 8.2%% CAGR in terms of revenue, the global market size will reach $ 384590 million by 2025, from $ 280760 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Biologics and Biosimilars business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Biologics and Biosimilars market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Biologics and Biosimilars, covering the supply chain analysis, impact assessment to the Biologics and Biosimilars market size growth rate in several scenarios, and the measures to be undertaken by Biologics and Biosimilars companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Tumor
Diabetes
Cardiovascular
Hemophilia
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Roche
Merck
Amgen
Sanofi-Aventis
Johnson & Johnson
AbbVie
Eli Lilly
Pfizer
Novartis
Novo Nordisk
Innovent
Ganlee
Dong Bao
3sbio
Biotech
CP Guojian
Gelgen
Changchun High Tech

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Biologics and Biosimilars consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Biologics and Biosimilars market by identifying its various subsegments.
Focuses on the key global Biologics and Biosimilars manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Biologics and Biosimilars with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Biologics and Biosimilars submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biologics and Biosimilars Consumption 2015-2025
2.1.2 Biologics and Biosimilars Consumption CAGR by Region
2.2 Biologics and Biosimilars Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Interferon
2.2.3 Erythropoietin
2.2.4 Insulin
2.2.5 Vaccines
2.2.6 Others
2.3 Biologics and Biosimilars Consumption by Type
2.3.1 Global Biologics and Biosimilars Consumption Market Share by Type (2015-2020)
2.3.2 Global Biologics and Biosimilars Revenue and Market Share by Type (2015-2020)
2.3.3 Global Biologics and Biosimilars Sale Price by Type (2015-2020)
2.4 Biologics and Biosimilars Segment by Application
2.4.1 Tumor
2.4.2 Diabetes
2.4.3 Cardiovascular
2.4.4 Hemophilia
2.4.5 Others
2.5 Biologics and Biosimilars Consumption by Application
2.5.1 Global Biologics and Biosimilars Consumption Market Share by Type (2015-2020)
2.5.2 Global Biologics and Biosimilars Value and Market Share by Type (2015-2020)
2.5.3 Global Biologics and Biosimilars Sale Price by Type (2015-2020)

3 Global Biologics and Biosimilars by Company
3.1 Global Biologics and Biosimilars Sales Market Share by Company
3.1.1 Global Biologics and Biosimilars Sales by Company (2018-2020)
3.1.2 Global Biologics and Biosimilars Sales Market Share by Company (2018-2020)
3.2 Global Biologics and Biosimilars Revenue Market Share by Company
3.2.1 Global Biologics and Biosimilars Revenue by Company (2018-2020)
3.2.2 Global Biologics and Biosimilars Revenue Market Share by Company (2018-2020)
3.3 Global Biologics and Biosimilars Sale Price by Company
3.4 Global Biologics and Biosimilars Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Biologics and Biosimilars Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Biologics and Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Biologics and Biosimilars by Regions
4.1 Biologics and Biosimilars by Regions
4.2 Americas Biologics and Biosimilars Consumption Growth
4.3 APAC Biologics and Biosimilars Consumption Growth
4.4 Europe Biologics and Biosimilars Consumption Growth
4.5 Middle East & Africa Biologics and Biosimilars Consumption Growth

5 Americas
5.1 Americas Biologics and Biosimilars Consumption by Countries
5.1.1 Americas Biologics and Biosimilars Consumption by Countries (2015-2020)
5.1.2 Americas Biologics and Biosimilars Value by Countries (2015-2020)
5.2 Americas Biologics and Biosimilars Consumption by Type
5.3 Americas Biologics and Biosimilars Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Biologics and Biosimilars Consumption by Regions
6.1.1 APAC Biologics and Biosimilars Consumption by Regions (2015-2020)
6.1.2 APAC Biologics and Biosimilars Value by Regions (2015-2020)
6.2 APAC Biologics and Biosimilars Consumption by Type
6.3 APAC Biologics and Biosimilars Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Biologics and Biosimilars by Countries
7.1.1 Europe Biologics and Biosimilars Consumption by Countries (2015-2020)
7.1.2 Europe Biologics and Biosimilars Value by Countries (2015-2020)
7.2 Europe Biologics and Biosimilars Consumption by Type
7.3 Europe Biologics and Biosimilars Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Biologics and Biosimilars by Countries
8.1.1 Middle East & Africa Biologics and Biosimilars Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Biologics and Biosimilars Value by Countries (2015-2020)
8.2 Middle East & Africa Biologics and Biosimilars Consumption by Type
8.3 Middle East & Africa Biologics and Biosimilars Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Biologics and Biosimilars Distributors
10.3 Biologics and Biosimilars Customer

11 Global Biologics and Biosimilars Market Forecast
11.1 Global Biologics and Biosimilars Consumption Forecast (2021-2025)
11.2 Global Biologics and Biosimilars Forecast by Regions
11.2.1 Global Biologics and Biosimilars Forecast by Regions (2021-2025)
11.2.2 Global Biologics and Biosimilars Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Biologics and Biosimilars Forecast by Type
11.8 Global Biologics and Biosimilars Forecast by Application

12 Key Players Analysis
12.1 Roche
12.1.1 Company Information
12.1.2 Biologics and Biosimilars Product Offered
12.1.3 Roche Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Roche Latest Developments
12.2 Merck
12.2.1 Company Information
12.2.2 Biologics and Biosimilars Product Offered
12.2.3 Merck Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Merck Latest Developments
12.3 Amgen
12.3.1 Company Information
12.3.2 Biologics and Biosimilars Product Offered
12.3.3 Amgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Amgen Latest Developments
12.4 Sanofi-Aventis
12.4.1 Company Information
12.4.2 Biologics and Biosimilars Product Offered
12.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Sanofi-Aventis Latest Developments
12.5 Johnson & Johnson
12.5.1 Company Information
12.5.2 Biologics and Biosimilars Product Offered
12.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Johnson & Johnson Latest Developments
12.6 AbbVie
12.6.1 Company Information
12.6.2 Biologics and Biosimilars Product Offered
12.6.3 AbbVie Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 AbbVie Latest Developments
12.7 Eli Lilly
12.7.1 Company Information
12.7.2 Biologics and Biosimilars Product Offered
12.7.3 Eli Lilly Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Eli Lilly Latest Developments
12.8 Pfizer
12.8.1 Company Information
12.8.2 Biologics and Biosimilars Product Offered
12.8.3 Pfizer Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Pfizer Latest Developments
12.9 Novartis
12.9.1 Company Information
12.9.2 Biologics and Biosimilars Product Offered
12.9.3 Novartis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Novartis Latest Developments
12.10 Novo Nordisk
12.10.1 Company Information
12.10.2 Biologics and Biosimilars Product Offered
12.10.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Novo Nordisk Latest Developments
12.11 Innovent
12.11.1 Company Information
12.11.2 Biologics and Biosimilars Product Offered
12.11.3 Innovent Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Innovent Latest Developments
12.12 Ganlee
12.12.1 Company Information
12.12.2 Biologics and Biosimilars Product Offered
12.12.3 Ganlee Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 Ganlee Latest Developments
12.13 Dong Bao
12.13.1 Company Information
12.13.2 Biologics and Biosimilars Product Offered
12.13.3 Dong Bao Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.13.4 Main Business Overview
12.13.5 Dong Bao Latest Developments
12.14 3sbio
12.14.1 Company Information
12.14.2 Biologics and Biosimilars Product Offered
12.14.3 3sbio Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.14.4 Main Business Overview
12.14.5 3sbio Latest Developments
12.15 Biotech
12.15.1 Company Information
12.15.2 Biologics and Biosimilars Product Offered
12.15.3 Biotech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.15.4 Main Business Overview
12.15.5 Biotech Latest Developments
12.16 CP Guojian
12.16.1 Company Information
12.16.2 Biologics and Biosimilars Product Offered
12.16.3 CP Guojian Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.16.4 Main Business Overview
12.16.5 CP Guojian Latest Developments
12.17 Gelgen
12.17.1 Company Information
12.17.2 Biologics and Biosimilars Product Offered
12.17.3 Gelgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.17.4 Main Business Overview
12.17.5 Gelgen Latest Developments
12.18 Changchun High Tech
12.18.1 Company Information
12.18.2 Biologics and Biosimilars Product Offered
12.18.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.18.4 Main Business Overview
12.18.5 Changchun High Tech Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Biologics and Biosimilars Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Monoclonal Antibodies
Table 5. Major Players of Interferon
Table 6. Major Players of Erythropoietin
Table 7. Major Players of Insulin
Table 8. Major Players of Vaccines
Table 9. Major Players of Others
Table 10. Global Consumption Sales by Type (2015-2020)
Table 11. Global Biologics and Biosimilars Consumption Market Share by Type (2015-2020)
Table 12. Global Biologics and Biosimilars Revenue by Type (2015-2020) ($ million)
Table 13. Global Biologics and Biosimilars Value Market Share by Type (2015-2020) ($ Millions)
Table 14. Global Biologics and Biosimilars Sale Price by Type (2015-2020)
Table 15. Global Consumption Sales by Application (2015-2020)
Table 16. Global Biologics and Biosimilars Consumption Market Share by Application (2015-2020)
Table 17. Global Biologics and Biosimilars Value by Application (2015-2020)
Table 18. Global Biologics and Biosimilars Value Market Share by Application (2015-2020)
Table 19. Global Biologics and Biosimilars Sale Price by Application (2015-2020)
Table 20. Global Biologics and Biosimilars Sales by Company (2017-2019) (K Units)
Table 21. Global Biologics and Biosimilars Sales Market Share by Company (2017-2019)
Table 22. Global Biologics and Biosimilars Revenue by Company (2017-2019) ($ Millions)
Table 23. Global Biologics and Biosimilars Revenue Market Share by Company (2017-2019)
Table 24. Global Biologics and Biosimilars Sale Price by Company (2017-2019)
Table 25. Global Biologics and Biosimilars Manufacturing Base Distribution and Sales Area by Manufacturers
Table 26. Players Biologics and Biosimilars Products Offered
Table 27. Biologics and Biosimilars Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 28. Global Biologics and Biosimilars Consumption by Regions 2015-2020 (K Units)
Table 29. Global Biologics and Biosimilars Consumption Market Share by Regions 2015-2020
Table 30. Global Biologics and Biosimilars Value by Regions 2015-2020 ($ Millions)
Table 31. Global Biologics and Biosimilars Value Market Share by Regions 2015-2020
Table 32. Americas Biologics and Biosimilars Consumption by Countries (2015-2020) (K Units)
Table 33. Americas Biologics and Biosimilars Consumption Market Share by Countries (2015-2020)
Table 34. Americas Biologics and Biosimilars Value by Countries (2015-2020) ($ Millions)
Table 35. Americas Biologics and Biosimilars Value Market Share by Countries (2015-2020)
Table 36. Americas Biologics and Biosimilars Consumption by Type (2015-2020) (K Units)
Table 37. Americas Biologics and Biosimilars Consumption Market Share by Type (2015-2020)
Table 38. Americas Biologics and Biosimilars Consumption by Application (2015-2020) (K Units)
Table 39. Americas Biologics and Biosimilars Consumption Market Share by Application (2015-2020)
Table 40. APAC Biologics and Biosimilars Consumption by Regions (2015-2020) (K Units)
Table 41. APAC Biologics and Biosimilars Consumption Market Share by Regions (2015-2020)
Table 42. APAC Biologics and Biosimilars Value by Regions (2015-2020) ($ Millions)
Table 43. APAC Biologics and Biosimilars Value Market Share by Regions (2015-2020)
Table 44. APAC Biologics and Biosimilars Consumption by Type (2015-2020) (K Units)
Table 45. APAC Biologics and Biosimilars Consumption Market Share by Type (2015-2020)
Table 46. APAC Biologics and Biosimilars Consumption by Application (2015-2020) (K Units)
Table 47. APAC Biologics and Biosimilars Consumption Market Share by Application (2015-2020)
Table 48. Europe Biologics and Biosimilars Consumption by Countries (2015-2020) (K Units)
Table 49. Europe Biologics and Biosimilars Consumption Market Share by Countries (2015-2020)
Table 50. Europe Biologics and Biosimilars Value by Countries (2015-2020) ($ Millions)
Table 51. Europe Biologics and Biosimilars Value Market Share by Countries (2015-2020)
Table 52. Europe Biologics and Biosimilars Consumption by Type (2015-2020) (K Units)
Table 53. Europe Biologics and Biosimilars Consumption Market Share by Type (2015-2020)
Table 54. Europe Biologics and Biosimilars Consumption by Application (2015-2020) (K Units)
Table 55. Europe Biologics and Biosimilars Consumption Market Share by Application (2015-2020)
Table 56. Middle East & Africa Biologics and Biosimilars Consumption by Countries (2015-2020) (K Units)
Table 57. Middle East & Africa Biologics and Biosimilars Consumption Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Biologics and Biosimilars Value by Countries (2015-2020) ($ Millions)
Table 59. Middle East & Africa Biologics and Biosimilars Value Market Share by Countries (2015-2020)
Table 60. Middle East & Africa Biologics and Biosimilars Consumption by Type (2015-2020) (K Units)
Table 61. Middle East & Africa Biologics and Biosimilars Consumption Market Share by Type (2015-2020)
Table 62. Middle East & Africa Biologics and Biosimilars Consumption by Application (2015-2020) (K Units)
Table 63. Middle East & Africa Biologics and Biosimilars Consumption Market Share by Application (2015-2020)
Table 64. Biologics and Biosimilars Distributors List
Table 65. Biologics and Biosimilars Customer List
Table 66. Global Biologics and Biosimilars Consumption Forecast by Countries (2021-2025) (K Units)
Table 67. Global Biologics and Biosimilars Consumption Market Forecast by Regions
Table 68. Global Biologics and Biosimilars Value Forecast by Countries (2021-2025) ($ Millions)
Table 69. Global Biologics and Biosimilars Value Market Share Forecast by Regions
Table 70. Global Biologics and Biosimilars Consumption Forecast by Type (2021-2025) (K Units)
Table 71. Global Biologics and Biosimilars Consumption Market Share Forecast by Type (2021-2025)
Table 72. Global Biologics and Biosimilars Value Forecast by Type (2021-2025) ($ Millions)
Table 73. Global Biologics and Biosimilars Value Market Share Forecast by Type (2021-2025)
Table 74. Global Biologics and Biosimilars Consumption Forecast by Application (2021-2025) (K Units)
Table 75. Global Biologics and Biosimilars Consumption Market Share Forecast by Application (2021-2025)
Table 76. Global Biologics and Biosimilars Value Forecast by Application (2021-2025) ($ Millions)
Table 77. Global Biologics and Biosimilars Value Market Share Forecast by Application (2021-2025)
Table 78. Roche Product Offered
Table 79. Roche Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 80. Roche Main Business
Table 81. Roche Latest Developments
Table 82. Roche Basic Information, Company Total Revenue (in $ million), Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 83. Merck Product Offered
Table 84. Merck Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 85. Merck Main Business
Table 86. Merck Latest Developments
Table 87. Merck Basic Information, Company Total Revenue (in $ million), Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 88. Amgen Product Offered
Table 89. Amgen Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 90. Amgen Main Business
Table 91. Amgen Latest Developments
Table 92. Amgen Basic Information, Company Total Revenue (in $ million), Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 93. Sanofi-Aventis Product Offered
Table 94. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 95. Sanofi-Aventis Main Business
Table 96. Sanofi-Aventis Latest Developments
Table 97. Sanofi-Aventis Basic Information, Company Total Revenue (in $ million), Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 98. Johnson & Johnson Product Offered
Table 99. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 100. Johnson & Johnson Main Business
Table 101. Johnson & Johnson Latest Developments
Table 102. Johnson & Johnson Basic Information, Company Total Revenue (in $ million), Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 103. AbbVie Product Offered
Table 104. AbbVie Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 105. AbbVie Main Business
Table 106. AbbVie Latest Developments
Table 107. AbbVie Basic Information, Company Total Revenue (in $ million), Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 108. Eli Lilly Product Offered
Table 109. Eli Lilly Basic Information, Company Total Revenue (in $ million), Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 110. Eli Lilly Main Business
Table 111. Eli Lilly Latest Developments
Table 112. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 113. Pfizer Product Offered
Table 114. Pfizer Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 115. Pfizer Main Business
Table 116. Pfizer Latest Developments
Table 117. Pfizer Basic Information, Company Total Revenue (in $ million), Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 118. Novartis Product Offered
Table 119. Novartis Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 120. Novartis Main Business
Table 121. Novartis Latest Developments
Table 122. Novartis Basic Information, Company Total Revenue (in $ million), Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 123. Novo Nordisk Product Offered
Table 124. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 125. Novo Nordisk Main Business
Table 126. Novo Nordisk Latest Developments
Table 127. Novo Nordisk Basic Information, Company Total Revenue (in $ million), Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 128. Innovent Product Offered
Table 129. Innovent Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 130. Innovent Main Business
Table 131. Innovent Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 132. Innovent Latest Developments
Table 133. Ganlee Product Offered
Table 134. Ganlee Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 135. Ganlee Main Business
Table 136. Ganlee Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 137. Ganlee Latest Developments
Table 138. Dong Bao Product Offered
Table 139. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 140. Dong Bao Main Business
Table 141. Dong Bao Latest Developments
Table 142. Dong Bao Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 143. 3sbio Product Offered
Table 144. 3sbio Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 145. 3sbio Main Business
Table 146. 3sbio Latest Developments
Table 147. 3sbio Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 148. Biotech Product Offered
Table 149. Biotech Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 150. Biotech Main Business
Table 151. Biotech Latest Developments
Table 152. Biotech Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 153. CP Guojian Product Offered
Table 154. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 155. CP Guojian Main Business
Table 156. CP Guojian Latest Developments
Table 157. CP Guojian Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 158. Gelgen Product Offered
Table 159. Gelgen Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 160. Gelgen Main Business
Table 161. Gelgen Latest Developments
Table 162. Gelgen Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 163. Changchun High Tech Product Offered
Table 164. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 165. Changchun High Tech Main Business
Table 166. Changchun High Tech Latest Developments
Table 167. Changchun High Tech Basic Information, Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Biologics and Biosimilars
Figure 2. Biologics and Biosimilars Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Biologics and Biosimilars Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Biologics and Biosimilars Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Monoclonal Antibodies
Figure 7. Product Picture of Interferon
Figure 8. Product Picture of Erythropoietin
Figure 9. Product Picture of Insulin
Figure 10. Product Picture of Vaccines
Figure 11. Product Picture of Others
Figure 12. Global Biologics and Biosimilars Consumption Market Share by Type (2015-2020)
Figure 13. Global Biologics and Biosimilars Value Market Share by Type (2015-2020)
Figure 14. Biologics and Biosimilars Consumed in Tumor
Figure 15. Global Biologics and Biosimilars Market: Tumor (2015-2020) (K Units)
Figure 16. Global Biologics and Biosimilars Market: Tumor (2015-2020) ($ Millions)
Figure 17. Biologics and Biosimilars Consumed in Diabetes
Figure 18. Global Biologics and Biosimilars Market: Diabetes (2015-2020) (K Units)
Figure 19. Global Biologics and Biosimilars Market: Diabetes (2015-2020) ($ Millions)
Figure 20. Biologics and Biosimilars Consumed in Cardiovascular
Figure 21. Global Biologics and Biosimilars Market: Cardiovascular (2015-2020) (K Units)
Figure 22. Global Biologics and Biosimilars Market: Cardiovascular (2015-2020) ($ Millions)
Figure 23. Biologics and Biosimilars Consumed in Hemophilia
Figure 24. Global Biologics and Biosimilars Market: Hemophilia (2015-2020) (K Units)
Figure 25. Global Biologics and Biosimilars Market: Hemophilia (2015-2020) ($ Millions)
Figure 26. Biologics and Biosimilars Consumed in Others
Figure 27. Global Biologics and Biosimilars Market: Others (2015-2020) (K Units)
Figure 28. Global Biologics and Biosimilars Market: Others (2015-2020) ($ Millions)
Figure 29. Global Biologics and Biosimilars Consumption Market Share by Application (2015-2020)
Figure 30. Global Biologics and Biosimilars Value Market Share by Application (2015-2020)
Figure 31. Global Biologics and Biosimilars Sales Market Share by Company in 2017
Figure 32. Global Biologics and Biosimilars Sales Market Share by Company in 2019
Figure 33. Global Biologics and Biosimilars Revenue Market Share by Company in 2017
Figure 34. Global Biologics and Biosimilars Revenue Market Share by Company in 2019
Figure 35. Global Biologics and Biosimilars Sale Price by Company in 2019
Figure 36. Global Biologics and Biosimilars Consumption Market Share by Regions 2015-2020
Figure 37. Global Biologics and Biosimilars Value Market Share by Regions 2015-2020
Figure 38. Americas Biologics and Biosimilars Consumption 2015-2020 (K Units)
Figure 39. Americas Biologics and Biosimilars Value 2015-2020 ($ Millions)
Figure 40. APAC Biologics and Biosimilars Consumption 2015-2020 (K Units)
Figure 41. APAC Biologics and Biosimilars Value 2015-2020 ($ Millions)
Figure 42. Europe Biologics and Biosimilars Consumption 2015-2020 (K Units)
Figure 43. Europe Biologics and Biosimilars Value 2015-2020 ($ Millions)
Figure 44. Middle East & Africa Biologics and Biosimilars Consumption 2015-2020 (K Units)
Figure 45. Middle East & Africa Biologics and Biosimilars Value 2015-2020 ($ Millions)
Figure 46. Americas Biologics and Biosimilars Consumption Market Share by Countries in 2019
Figure 47. Americas Biologics and Biosimilars Value Market Share by Countries in 2019
Figure 48. Americas Biologics and Biosimilars Consumption Market Share by Type in 2019
Figure 49. Americas Biologics and Biosimilars Consumption Market Share by Application in 2019
Figure 50. United States Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 51. United States Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 52. Canada Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 53. Canada Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 54. Mexico Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 55. Mexico Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 56. APAC Biologics and Biosimilars Consumption Market Share by Countries in 2019
Figure 57. APAC Biologics and Biosimilars Value Market Share by Regions in 2019
Figure 58. APAC Biologics and Biosimilars Consumption Market Share by Type in 2019
Figure 59. APAC Biologics and Biosimilars Consumption Market Share by Application in 2019
Figure 60. China Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 61. China Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 62. Japan Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 63. Japan Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 64. Korea Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 65. Korea Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 66. Southeast Asia Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 67. Southeast Asia Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 68. India Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 69. India Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 70. Australia Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 71. Australia Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 72. Europe Biologics and Biosimilars Consumption Market Share by Countries in 2019
Figure 73. Europe Biologics and Biosimilars Value Market Share by Countries in 2019
Figure 74. Europe Biologics and Biosimilars Consumption Market Share by Type in 2019
Figure 75. Europe Biologics and Biosimilars Consumption Market Share by Application in 2019
Figure 76. Germany Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 77. Germany Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 78. France Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 79. France Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 80. UK Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 81. UK Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 82. Italy Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 83. Italy Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 84. Russia Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 85. Russia Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 86. Middle East & Africa Biologics and Biosimilars Consumption Market Share by Countries in 2019
Figure 87. Middle East & Africa Biologics and Biosimilars Value Market Share by Countries in 2019
Figure 88. Middle East & Africa Biologics and Biosimilars Consumption Market Share by Type in 2019
Figure 89. Middle East & Africa Biologics and Biosimilars Consumption Market Share by Application in 2019
Figure 90. Egypt Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 91. Egypt Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 92. South Africa Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 93. South Africa Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 94. Israel Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 95. Israel Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 96. Turkey Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 97. Turkey Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 98. GCC Countries Biologics and Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 99. GCC Countries Biologics and Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 100. Global Biologics and Biosimilars Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 101. Global Biologics and Biosimilars Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 102. Americas Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 103. Americas Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 104. APAC Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 105. APAC Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 106. Europe Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 107. Europe Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 108. Middle East & Africa Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 109. Middle East & Africa Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 110. United States Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 111. United States Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 112. Canada Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 113. Canada Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 114. Mexico Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 115. Mexico Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 116. Brazil Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 117. Brazil Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 118. China Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 119. China Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 120. Japan Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 121. Japan Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 122. Korea Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 123. Korea Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 124. Southeast Asia Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 125. Southeast Asia Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 126. India Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 127. India Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 128. Australia Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 129. Australia Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 130. Germany Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 131. Germany Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 132. France Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 133. France Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 134. UK Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 135. UK Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 136. Italy Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 137. Italy Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 138. Russia Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 139. Russia Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 140. Spain Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 141. Spain Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 142. Egypt Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 143. Egypt Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 144. South Africa Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 145. South Africa Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 146. Israel Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 147. Israel Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 148. Turkey Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 149. Turkey Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 150. GCC Countries Biologics and Biosimilars Consumption 2021-2025 (K Units)
Figure 151. GCC Countries Biologics and Biosimilars Value 2021-2025 ($ Millions)
Figure 152. Roche Biologics and Biosimilars Market Share (2018-2020)
Figure 153. Merck Biologics and Biosimilars Market Share (2018-2020)
Figure 154. Amgen Biologics and Biosimilars Market Share (2018-2020)
Figure 155. Sanofi-Aventis Biologics and Biosimilars Market Share (2018-2020)
Figure 156. Johnson & Johnson Biologics and Biosimilars Market Share (2018-2020)
Figure 157. AbbVie Biologics and Biosimilars Market Share (2018-2020)
Figure 158. Eli Lilly Biologics and Biosimilars Market Share (2018-2020)
Figure 159. Pfizer Biologics and Biosimilars Market Share (2018-2020)
Figure 160. Novartis Biologics and Biosimilars Market Share (2018-2020)
Figure 161. Novo Nordisk Biologics and Biosimilars Market Share (2018-2020)
Figure 162. Innovent Biologics and Biosimilars Market Share (2018-2020)
Figure 163. Ganlee Biologics and Biosimilars Market Share (2018-2020)
Figure 164. Dong Bao Biologics and Biosimilars Market Share (2018-2020)
Figure 165. 3sbio Biologics and Biosimilars Market Share (2018-2020)
Figure 166. Biotech Biologics and Biosimilars Market Share (2018-2020)
Figure 167. CP Guojian Biologics and Biosimilars Market Share (2018-2020)
Figure 168. Gelgen Biologics and Biosimilars Market Share (2018-2020)
Figure 169. Changchun High Tech Biologics and Biosimilars Market Share (2018-2020)

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $3660
USD $5490
USD $7320
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.